[Expression of multidrug resistance P-170 and @entity11092 and their correlation with clinical drug resistance in XXXX ].

@entity1 @entity1778 @entity11092 @entity3052
OBJECTIVE: To investigate the relevance between the expression of P-170 and @entity11092 and clinical drug resistance in @entity3052 . METHODS: The expression of P-170 and @entity11092 in mononuclear cells of bone marrows was analyzed by the immunohistochemical technique in 72 @entity3052 @entity1 . RESULTS: The expression of P-170 was positive in 46 and negative in 26 of the 72 post-chemotherapy @entity3052 @entity1 . The therapeutic effect of the P-170 positive expression @entity1 was significantly poorer than that of the negative expression @entity1 (P < 0.01). The expression of @entity11092 was positive in 39 and negative in 33 of the 72 post-chemotherapy @entity3052 @entity1 . The therapeutic effect of the @entity11092 positive expression @entity1 was significantly poorer than that in the negative expression @entity1 (P < 0.01). The expression of P-170 and @entity11092 had a significant concordance (Kappa = 0.427, P < 0.01). The sensitivity of P-170 and @entity11092 which were analyzed simultaneously was 97.5%, which was higher than that of P-170 (90%) or @entity11092 (77.5%) analyzed respectively in drug resistance @entity1 . CONCLUSION: The expression of P-170 and/or @entity11092 was significantly related with drug resistance in clinical chemotherapy. The therapeutic effect was significantly poorer in P-170 and/or @entity11092 positive expression @entity1 than that in negative expression @entity1 . These data suggest that P-170 and @entity11092 analyzed simultaneously can improve the value of diagnosis and prognosis in @entity1 with @entity1778 .
